$NAMS News

Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease

NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia

NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run

HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate